Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. These NTRK gene fusions are oncogenic drivers found in most tumour types at a low freq...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Oncol
Main Authors: Bebb, D. Gwyn, Banerji, Shantanu, Blais, Normand, Desmeules, Patrice, Gill, Sharlene, Grin, Andrea, Feilotter, Harriet, Hansen, Aaron R., Hyrcza, Martin, Krzyzanowska, Monika, Melosky, Barbara, Noujaim, Jonathan, Purgina, Bibiana, Ruether, Dean, Simmons, Christine E., Soulieres, Denis, Torlakovic, Emina Emilia, Tsao, Ming-Sound
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Guidelines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903287/
https://ncbi.nlm.nih.gov/pubmed/33467570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/curroncol28010053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados